exposure to tobacco products (Stewart et al., 2008) . Although some genetic alterations have been identified as occurring in a proportion of these neoplasms (inactivation of the p53 and p16 tumor suppressor genes, amplification of the epidermal growth factor receptor (EGFR), PIK3CA and cyclin D1 (CCND1) genes), these alterations alone cannot account for the complete neoplastic transformation of most SCCs (Singh, 2008) . In an effort to further identify genetic and gene expression changes that may play a functional role in tobacco-related squamous carcinomas, a cohort of carcinomas was subjected to global genetic and genomic analysis using oligonucleotide arrays querying both transcript and genomic content. We report the results of these studies here, with validation of one of the upregulated genes, EGFR-co-amplified and overexpressed protein (ECOP), which seems to have a functional significance in the biology of SCC.
From the expression array data, 1377 genes were found to be significantly differentially expressed (at least twofold difference, false discovery rate o0.01) between the cohorts of SCC and benign squamous mucosa (BSM) samples using the Kruskal-Wallis one-way ANOVA (analysis of variance) non-parametric test. As expected, unsupervised clustering analysis using these 1377 genes clearly segregated SCC samples from BSM, indicating profound differences in gene expression patterns (Figure 1 ). An additional metric was applied, which combines fold change, absolute difference and statistical significance to obtain a ranking of differentially expressed genes (Welsh et al., 2001a, b) . According to this metric, the probe sets that showed the largest degree of upregulation and downregulation in SCC relative to BSM are presented as Supplementary data. As one might expect, many of the highest-ranking upregulated genes have annotations of oncogenic properties or previous associations with neoplasia. Accordingly, many of the highest-ranking downregulated genes have annotation of tumor suppressor activity. The complete ranking of probe sets is presented in the Supplementary data.
The DNA from the tumor cohort was also subjected to genomic analysis using oligonucleotide microarrays querying single-nucleotide polymorphisms. Regularized copy number estimates across the entire genome on a per chromosome and SCC sample basis were generated.
Areas of low-level amplification (copy number increases of 1-2) were common and frequently involved large areas (>25 Mb) making it difficult to identify specific genes whose regulation may have been affected. In contrast, only two areas of high-level amplification were identified; both of which exhibited small minimally common regions. The first region, 11q13.3, occurred in 14% of our cohort and the second region, 7p11.2, occurred in 9.4% of our cohort. These regions have been previously identified as targets of amplification in SCC, and have been ascribed to amplification of the CCND1 gene and the EGFR gene, respectively.
In examining these regions for genes that were queried by the expression arrays employed, the 11q13.3 locus contained the genes CCND1, FGF4, FGF3, TME-M16A, FADD, FLJ42258, ORAOV1 and FGF19 with probes for the first five genes present on the arrays. Of these, CCND1, FADD and TMEM16A exhibited an overexpression relative to BSM that correlated directly to the amplification status of this locus. FGF3 and FGF4 were generally not expressed or expressed at low levels throughout the sample cohort (data not shown).
In examining the 7p11.2 locus, it was noted that in addition to EGFR, this locus contains the gene entitled EGFR-co-amplified and over-expressed protein (ECOP) based on the previous association of co-amplification at this locus in approximately one-third of glioblastoma multiforme tumors (Eley et al., 2002) . In our SCC cohort, although EGFR overexpression was limited to the 9% of the tumors exhibiting amplification at this locus, ECOP was found to be overexpressed in 90% of our cohort, regardless of gene amplification status (Figure 3) . Furthermore, the ECOP locus was never amplified independently of the EGFR locus and was only co-amplified with the EGFR locus in only 50% of the EGFR-amplified samples that we observed. (Note: we observed no significant difference in EGFR amplification across SCC primary site, that is, head and neck, lung, esophageal (w 2 P ¼ 0.22)). Thus, although EGFR overexpression through a genomic amplification mechanism may be selected during SCC tumorigenesis, ECOP overexpression seems to be caused by a transcriptional control mechanism rather than genomic amplification, and seems unrelated to gene amplification of EGFR. As ECOP has been identified in glioblastoma multiforme as a potential oncogenic factor, with pro-survival effects mediated by the NF-kB pathway (Park and James, 2005 ), but has not been studied in SCC, we decided to validate and further study the role of ECOP in SCC.
To validate the microarray transcript analysis, quantitative reverse transcriptase PCR for ECOP was performed on RNA from a subset of tumors and normal tissues in the cohort. The results indicate a clear upregulation of ECOP in SCC compared with BSM ( Figure 2a and c) that correlates well with the expression levels detected by microarray analysis of the same samples (r ¼ 0.76). These results confirmed that the ECOP transcript is overexpressed in approximately 90% of SCC.
To obtain validation from independent cohorts of tumors, publicly available microarray data that compare samples of SCC with BSM were obtained from the Oncomine database (http://www.oncomine.org). In all external data sets examined, ECOP transcript expression is consistently higher in SCC compared with BSM, with little overlap between these populations ( Figure 2d ) (Cromer et al., 2004; Ginos et al., 2004; Toruner et al., 2004; Talbot et al., 2005) . Figure 1 Clustered heatmap of gene expression profiling results. RNA samples were made into labeled probes and hybridized to U133A 2.0 GeneChips (Affymetrix, Santa Clara, CA, USA) using protocols, supplies and equipment supplied or specified by the manufacturer. Expression values, standard errors and present (P)-marginal (M)-absent (A) calls for each probe-set were generated from the raw data (.cel files) using a PM/MM model for gene expression (dChip, www.dchip.org). Using the P, M and A calls, genes that did not exhibit at least 75% P or M calls in at least one of the groups of the categorical variable being examined were screened out. After this, the Kruskal-Wallis non-parametric one-way analysis of variance was used to assess statistical significance. The resulting nominal P-values were corrected for multiple testing using a false discovery rate approach. A heatmap of the normalized gene expression measures for the 1377 genes identified as differentially expressed is shown, in which rows represent samples and columns represent genes. Two-way clustering was performed using the Euclidean distance metric for samples and a correlation-based metric for genes using the unweighted pair group method with arithmetic mean (UPGMA) for both sample and gene tree construction. (Note: the gene tree was excluded from the figure). SCC, squamous cell carcinoma; BSM, benign squamous mucosa.
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To determine whether ECOP protein levels correlate with transcript levels in SCC and BSM levels, a rabbit polyclonal antiserum was generated to a synthetic ECOP peptide. Affinity purified antiserum recognizes ECOP in SCC-9, a SCC-derived cell line, as two protein species of 21.2 and 19.7 kDa (Supplementary data). The proteins recognized by this antiserum are specifically reduced by small interfering RNA (siRNA) oligonucleotides directed against the ECOP transcript, but not by scrambled oligonucleotide controls (Supplementary data). Using this antibody in immunoblots of protein extracts of SCC and BSM, ECOP protein is found in higher levels in extracts of SCC versus the levels in BSM (Figure 2b) .
To validate the gene copy number estimates obtained from single-nucleotide polymorphism array data analysis, quantitative PCR for the ECOP and EGFR loci was performed on a subset of samples. Figure 3a shows that the regularized copy numbers of the two loci constructed from the single-nucleotide polymorphism array data are highly correlated to the results of quantitative PCR. The amplification status of EGFR, accessed from the single-nucleotide polymorphism array data, was used to stratify the expression of ECOP and EGFR in our cohort. Figure 3b shows that EGFR overexpression is completely dependent on EGFR amplification, whereas ECOP overexpression relative to BSM is independent of EGFR amplification status.
To provide preliminary evidence that ECOP expression has functional significance in SCC, ECOP gene products were knocked down by oligonucleotide siRNA sequences in a SCC-derived cell line (SCC-9). As ECOP knockdown had previously been shown to effect cell Internal control of B2M-gene-specific primers were forward: 5 0 -TGTGCTCGCGCTACTCTCTC-3 0 and reverse: 5 0 -TCTCTGCTGGATGACGTGAG-3 0 . Expression of these genes was calculated as the log of the ratio of ECOP to B2M. (b) Representative western blot of tissue samples for ECOP overexpression. An anti-ECOP rabbit polyclonal antibody that we developed was used to probe for ECOP, and a commercial antibody (Cell Signaling Technology, Beverly, MA, USA) for a/b-tubulin served as the loading control. (c) Summary of ECOP overexpression, normalized against BSM, assessed by microarray, qRT-PCR and quantification of western blots using ImageJ software from NIH, USA. All intervals are 95% confidence intervals, such that intervals that do not overlap are significant differences, Po0.05. (d) Publicly available data from the Oncomine database of ECOP in studies examining BSM and various SCCs was extracted directly from the Oncomine website interface. In each of these independent studies of SCC, a consistent ECOP overexpression is observed.
A Baras et al viability in the cervical adenocarcinoma-derived HeLa cell line (Park and James, 2005) , we performed the experiments in SCC-9 in tandem with HeLa. From quantitative reverse transcriptase PCR and immunoblot analysis, SCC-9 exhibits ECOP expression comparable with that observed in tissue samples of SCC (data not shown). Two different siRNAs to ECOP, one targeting the coding sequence and one targeting the 3 0 -UTR, are able to achieve significant knockdown at the protein level (Figure 4a) . After 48 h of knockdown, cell viability was significantly decreased in both the HeLa and the SCC-9 cell lines with anti-ECOP siRNA oligonucleotides, compared with siRNA control oligonucleotides, averaged over three independent experiments each of which was run in three technical replicates (Figure 4b ). Following this line of evidence, we quantified cell death by a fluorescent TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling) assay counterstained with DAPI (4 0 ,6-diamidino-2-phenylindole). As expected, we observed a significant increase in the percentage of TUNNEL-positive nuclei with ECOP knockdown using both siRNAs in SCC-9 and HeLa (Figure 4c) .
The work of Park and James in the HeLa and HEK 293T cell lines showed that the pro-survival phenotype of ECOP overexpression might function through the NF-kB pathway. To address whether this was also occurring in the SCC-derived cell line employed in Figure 3 Epidermal growth factor receptor (EGFR) co-amplified and overexpressed protein (ECOP) overexpression is not due to EGFR co-amplification in squamous cell carcinoma (SCC). (a) The top axis shows copy number estimates of benign squamous mucosa (BSM) and SCC samples predicted to harbor EGFR and/or ECOP amplifications extracted from the single-nucleotide polymorphism (SNP) array data, labeled ECOP or EGFR SNP array in the legend. Validations of these estimates by quantitative PCR (qPCR) for these loci with technical replicates of three and 95% confidence intervals are labeled as ECOP or EGFR qPCR in the legend. Primers for the EGFR, ECOP and control locus (CL) were EGFR-forward: 5 0 -AAAAGGCAGTGGCTGAATTG-3 0 , EGFR-reverse: 5 0 -AGGCGGTGGTTACGAGTATG-3 0 , ECOP-forward: 5 0 -AAGACAGACATGTAGACCAATGGA-3 0 , ECOP-reverse: 5 0 -GCTG AGAGATGGAAGCAACC-3 0 , CL-forward: 5 0 -TCCATCCTTTATGTTTGGGTTC-3 0 , CL-reverse: 5 0 -GGGACACGTGTAACAA AATCAG-3 0 . The control region was selected by examining the SNP array data for a copy number call of 2 across all samples. A dotted line marks copy number 2, the expected normal state. The bottom axis shows expression of the ECOP/EGFR transcript as assessed by microarray in parallel to the same samples presented in the top axis, 95% confidence intervals are based on the standard errors outputted from dchip (www.dchip.org). (b) Expression by microarray for the EGFR and ECOP across our tumor cohort stratified on EGFR amplification status, constructed from the SNP array data. The data is normalized against BSM expression, so that if 95% confidence intervals cross unity, then no statistical difference in relation to BSM is present at Po0.05.
A Baras et al these experiments, we examined NF-kB activity through luciferase reporter in the context of ECOP knockdown. As observed by Park and James, ECOP knockdown results in decreased NF-kB reporter activity in HeLa; however, this was not the case for SCC-9 (Figure 4d ).
Discussion
Epidermal growth factor receptor co-amplified and overexpressed protein derived its current nomenclature from previous investigations of glioblastoma multiforme that observed that ECOP is adjacent to EGFR by only Cell viability, as quantified by Promega's Cell Titer Blue assay (Promega, Fitchburg, WI, USA), is significantly decreased relative to control with both siRNAs. Data is normalized relative to the control siRNA condition per cell line and presented as percent viable relative to this control with 95% confidence intervals of three independent experiments each conducted in technical replicates of three. Intervals that do not overlap represent a significant (Po0.05) difference. (c) Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNNEL)-positive nuclei were labeled with fluorescein isothiocyanate-conjugated dUTP using Roche's in situ Cell Death Detection Kit (Roche, Madison, WI, USA). All nuclei were counterstained with DAPI (4 0 ,6-diamidino-2-phenylindole). Greater than B400 nuclei were counted in each condition and results are presented as averages and 95% confidence intervals of three experiments normalized to controls. (d) The 5X NF-kB element from pNF-kB-Luc (Stratagene, Cedar Creek, TX, USA) was cloned into pGL3 promoter (Promega). With only control siRNA, the introduction of the NF-kB element into pGL3 promoter resulted in a significant normalized luciferase activity. hMGFP, a cytomegalovirus-driven modified green fluorescent protein vector from Promega, was used as a control to quantify transfection efficiency. Briefly, background corrected fluorescence (ex. 480, em. 520) was measured from lysates in 96-well plate readers. After this, standard luciferase assay (Promega) was used to detect reporter activity. ECOP knockdown resulted in significantly decreased normalized NF-kB activity only in HeLa. SCC-9 and HeLa cell lines (ATCC, Manassas, VA, USA) were grown in Dulbecco's modied Eagle's medium/F12 medium supplemented with 10% fetal bovine serum. Two siRNAs were designed targeting ECOP mRNA; the first in the coding sequence 5 0 -GGACUCUAUCCAACCUAUU-3 0 , and the second in the 3 0 -UTR 5 0 -GACAGGAGAAGUACUGACU-3 0 . The annealed double-stranded siRNAs for the aforementioned sequences along with a control siRNA were acquired from Ambion (Austin, TX, USA). siRNAs, 50 nM, were introduced into cells using Lipofectamine 2000 (Invitrogen-Life Technologies, Carlsbad, CA, USA) according the manufactures protocols. Cells were plated in 96-well plates at a density of 5000-10 000 cells per well. At 24 h after plating, siRNA/reporter plasmids were introduced. NF-kB activity was measured at 24-h post-transfection, viability was measured using Cell Titer Blue (Promega) at 48-h post-transfection, and TUNNEL assays were conducted 72-h post-transfection.
ECOP up-regulation in SCC A Baras et al 0.4 Mb and is co-amplified with EGFR in approximately one-third of the 40% of glioblastoma multiforme that harbor the EGFR amplification (Eley et al., 2002) . In the SCC cohort examined here, EGFR was amplified in only B9% of cases and no significant difference was detected with respect to the tumor site of origin, that is, lung, head and neck, esophageal (w 2 P ¼ 0.22). In addition, ECOP was co-amplified in only half of these cases and never amplified independently of the EGFR locus. This implies that the amplification of the ECOP locus is, in fact, a bystander to the focus of this amplification (EGFR), at least in SCC. In contrast, ECOP transcript and protein levels are elevated in 90% of SCC, regardless of the gene copy number status. This information suggests that ECOP activity has been selected for during neoplastic transformation in squamous epithelium independent from EGFR amplification.
Our analyses validated the microarray profiling by showing ECOP transcript upregulation in SCC in comparison with BSM by quantitative reverse transcriptase PCR as well as upregulated levels of protein by immunoblot. In addition, a survey of publicly available microarray data, which had previously queried SCC, validated our findings in other sample cohorts, although to our knowledge, the specific finding of ECOP upregulation in SCC has not been previously reported or validated by other means. In an SCC-derived cell line (SCC-9) ECOP gene product knockdown consistently resulted in decreased cell viability and increased the percentage of TUNNEL-positive nuclei, confirming the findings found in other cell lines that the expression of this gene confers a pro-survival phenotype. Interestingly though, our preliminary work in SCC-9 indicates that this is not occurring through an NF-kB-mediated process in SCC, which is in contrast to the evidence shown in previous work on HeLa and HEK 293T cell lines. Although further validation and examination of the mechanisms of this effect in additional SCC-derived cell lines are warranted, we believe that our analysis has identified ECOP as a consistently (>90%) dysregulated gene in SCC that confers a pro-neoplastic phenotype to the tumor cells. Our analyses further reveal that unlike previous neoplasms studied, ECOP upregulation in SCC is not primarily due to gene amplification, and seems to be primarily a transcriptional regulatory effect.
Conflict of interest
The authors declare no conflict of interest.
